

# Positions

## Access

- [Access to healthcare \(PDF 0.3 MB\)](#)
- [Value-Based Healthcare \(PDF 0.1 MB\)](#)

## R&D

- [Animal research \(PDF 0.2 MB\)](#)
- [Clinical study transparency \(PDF 0.2 MB\)](#)
- [Medicines for Patients with Rare Diseases \(PDF 0.2 MB\)](#)
- [Post-trial Access \(PDF 0.1 MB\)](#)
- [Pre-Approval Access to Novartis Products through MAPs \(PDF 0.3 MB\)](#)
- [Responsible Clinical Trials \(PDF 0.1 MB\)](#)
- [Novartis Commitment to Diversity in Clinical Trials \(PDF 0.2 MB\)](#)
- [Novartis Position on Investigator Initiated Trials \(IITs\) and Investigator Initiated Research \(IIRs\) \(PDF 0.2 MB\)](#)
- [Position on Scientific Publications \(PDF 0.2 MB\)](#)

## Quality and safety of medicines

- [Falsified Medical Products \(PDF 0.3 MB\)](#)

## Intellectual property

- [Intellectual Property \(PDF 0.3 MB\)](#)
- [Regulatory data protection \(PDF 0.3 MB\)](#)

## Ethics

- [Novartis Position on Collaborating with Patient Organizations \(PDF 0.2 MB\)](#)

## Biologics

- [Innovative Biologic Medicines and Biosimilars \(PDF 0.1 MB\)](#)

## Environment

- [Pharmaceuticals in the environment \(PDF 0.2 MB\)](#)

## Taxation

- [Novartis Tax Policy Statement \(PDF 0.2 MB\)](#)

---

**Source URL:** <https://prod1.novartis.com/node/639291>

**List of links present in page**

1. <https://prod1.novartis.com/node/639291>
2. [https://prod1.novartis.com/sites/novartis\\_com/files/access-to-healthcare-perspective.pdf](https://prod1.novartis.com/sites/novartis_com/files/access-to-healthcare-perspective.pdf)
3. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-position-on-value-based-healthcare.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-position-on-value-based-healthcare.pdf)
4. [https://prod1.novartis.com/sites/novartis\\_com/files/animal-research.pdf](https://prod1.novartis.com/sites/novartis_com/files/animal-research.pdf)
5. [https://prod1.novartis.com/sites/novartis\\_com/files/clinical-trial-data-transparency.pdf](https://prod1.novartis.com/sites/novartis_com/files/clinical-trial-data-transparency.pdf)
6. [https://prod1.novartis.com/sites/novartis\\_com/files/medicines-for-patients-with-rare-diseases.pdf](https://prod1.novartis.com/sites/novartis_com/files/medicines-for-patients-with-rare-diseases.pdf)
7. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-position-on-post-trial-access.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-position-on-post-trial-access.pdf)
8. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-position-pre-approval-access.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-position-pre-approval-access.pdf)
9. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-position-on-responsible-clinical-trials.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-position-on-responsible-clinical-trials.pdf)
10. [https://prod1.novartis.com/sites/novartis\\_com/files/commitment-for-diversity-in-clinical-trials.pdf](https://prod1.novartis.com/sites/novartis_com/files/commitment-for-diversity-in-clinical-trials.pdf)
11. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-investigator-initiated-trials.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-investigator-initiated-trials.pdf)
12. [https://prod1.novartis.com/sites/novartis\\_com/files/position-on-scientific-publications.pdf](https://prod1.novartis.com/sites/novartis_com/files/position-on-scientific-publications.pdf)
13. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-position-on-falsified-medical-products.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-position-on-falsified-medical-products.pdf)
14. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-intellectual-property-position.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-intellectual-property-position.pdf)
15. [https://prod1.novartis.com/sites/novartis\\_com/files/regulatory-data-protection.pdf](https://prod1.novartis.com/sites/novartis_com/files/regulatory-data-protection.pdf)
16. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-position-on-collaborating-with-patient-organizations.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-position-on-collaborating-with-patient-organizations.pdf)
17. [https://prod1.novartis.com/sites/novartis\\_com/files/biosimilars-key-regulatory-and-market-access-aspects.pdf](https://prod1.novartis.com/sites/novartis_com/files/biosimilars-key-regulatory-and-market-access-aspects.pdf)
18. [https://prod1.novartis.com/sites/novartis\\_com/files/pharmaceuticals-environment.pdf](https://prod1.novartis.com/sites/novartis_com/files/pharmaceuticals-environment.pdf)
19. [https://prod1.novartis.com/sites/novartis\\_com/files/tax-policy-statement.pdf](https://prod1.novartis.com/sites/novartis_com/files/tax-policy-statement.pdf)
20. <https://prod1.novartis.com/node/639291/printable/print>
21. <https://prod1.novartis.com/node/639291/printable/pdf>